Biotricity, Inc. (OTCMKTS:BTCY) Director Sells $53,062.24 in Stock

Biotricity, Inc. (OTCMKTS:BTCY) Director David A. Rosa sold 17,228 shares of the business’s stock in a transaction on Thursday, October 7th. The stock was sold at an average price of $3.08, for a total value of $53,062.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of OTCMKTS BTCY opened at $3.15 on Thursday. The business’s 50-day moving average price is $3.20 and its two-hundred day moving average price is $3.04. Biotricity, Inc. has a one year low of $0.67 and a one year high of $4.25.

Biotricity (OTCMKTS:BTCY) last issued its earnings results on Monday, August 16th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.60 million. On average, equities research analysts anticipate that Biotricity, Inc. will post -0.33 EPS for the current fiscal year.

Several research firms recently weighed in on BTCY. Northland Securities began coverage on Biotricity in a research report on Thursday, July 1st. They set an “outperform” rating and a $7.00 price target on the stock. Maxim Group reissued a “buy” rating and set a $6.00 price target on shares of Biotricity in a research report on Friday, September 10th. Finally, Noble Financial started coverage on Biotricity in a research report on Thursday, July 1st. They set an “outperform” rating and a $7.00 price target on the stock.

Biotricity Company Profile

Biotricity, Inc is a medical technology company, which is focused on biometric data monitoring solutions. It also involves in delivering, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.

Further Reading: The benefits and drawbacks of dollar cost averaging

Receive News & Ratings for Biotricity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotricity and related companies with MarketBeat.com's FREE daily email newsletter.